Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
Abstract Neratinib is a tyrosine kinase inhibitor that is used for the therapy of patients with HER2+ breast tumors. However, despite its clinical benefit, resistance to the drug may arise. Here we have created cellular models of neratinib resistance to investigate the mechanisms underlying such res...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-08-01
|
| Series: | Oncogenesis |
| Online Access: | https://doi.org/10.1038/s41389-024-00531-4 |